Total Live Articles: 447

Transient Ischaemic Attack (TIA)

National Clinical Guideline for Stroke 2023 Edition.

NICE Guideline [NG128] Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. Last updated: Apr 2022

Transient Ischaemic Attack (TIA)

A transient ischaemic attack (TIA) is defined as an acute loss of focal cerebral or ocular function with symptoms lasting less than 24 hours.

This updated UKMLA guide to ischaemic stroke is based on National Clinical Guideline for Stroke and NICE NG128, which covers guidelines on initial assessment, investigations, and management.

Note on TIA definition:

  • Traditional teaching and UK guidance, including NICE, NICE CKS and the UK National Clinical Guideline for Stroke 2023, define stroke and TIA using the 24-hour clinical cut-off
  • However, some modern definitions, particularly from the AHA/ASA, use a tissue-based definition
    • Under this definition, TIA refers to a transient focal neurological deficit caused by ischaemia without evidence of acute infarction
    • Therefore, if symptoms fully resolve but imaging shows acute infarction, the event is classified as an ischaemic stroke rather than a TIA

This is included because one may encounter both definitions in clinical practice and in different guideline sources.

Causes and Clinical Features

TIA is a transient, ischaemic stroke-like event and an important warning sign for future ischaemic stroke

  • It shares similar risk factors and clinical features with ischaemic stroke, i.e. sudden-onset focal neurological deficits that are typically painless
  • The key distinction is that TIA symptoms are temporary and fully resolve within 24 hours
  • For a more detailed explanation of clinical features and vascular territory patterns, see the Stroke (Overview) article

Amaurosis fugax is a transient monocular visual loss caused by temporary ischaemia of the retina or optic nerve. It can be considered a form of TIA affecting the eye and is commonly associated with carotid artery disease.

Assessment and Management

Primary Care / Emergency Department

Immediate steps if TIA is suspected:

  • Exclude hypoglycaemia
  • Offer aspirin 300 mg immediately unless contraindicated (e.g. allergy, patients on anticoagulants)
  • Refer within 24 hours to a stroke specialist clinician (acute stroke unit or neurovascular clinic)

Risk stratification tools (e.g. ABCD2 score) are NOT recommended to determine how urgently a patient needs to be referred or seen.

Due to the substantial risk of a completed stroke in the first few days following a TIA, all cases must be treated as urgent and assessed within that 24-hour window.

Secondary Care – Investigations

Imaging to be considered in secondary care:

Imaging Indications
Non-contrast CT head ALL patients who take anticoagulants or have a bleeding disorder → urgent non-contrast CT head to exclude intracranial haemorrhage

Otherwise, it should NOT be performed routinely unless there is clinical suspicion of an alternative diagnosis that CT could detect

This contrasts with the approach in suspected stroke, where non-contrast CT head is done in ALL patients urgently

MRI head Primary imaging modality to detect ischaemia and support the diagnosis of TIA.

Indicated when the specialist determines the results will influence management, such as reducing diagnostic uncertainty or confirming the vascular territory of the stroke before starting dual antiplatelet therapy or planning carotid surgery

Carotid imaging (duplex ultrasound, CT / MR angiogram) Indicated urgently (within 24 hours of specialist assessment) for patients who have anterior circulation symptoms and are considered potential candidates for carotid surgery
Other investigations:

Investigation Description / indications
Cardiac monitoring Baseline ECG – all patients

Anyone with a suspected TIA or ischaemic stroke who is not already diagnosed with atrial fibrillation or atrial flutter should undergo cardiac monitoring (Holter or inpatient telemetry) for at least 24 hours

Transhythoracic echocardiogram Indicated if:

  • Clinical history / ECG suggestive of structural heart disease, or
  • Possible cardioembolic source (e.g. multiple infarcts in different arterial territories)
Blood tests
  • Standard laboratory studies (FBC, U&E, HbA1c, lipid profile etc.)
  • Screen OSA (as it is an independent risk factor)

If the patient is young or the underlying cause remains unknown, consider targeted screening of:

Secondary Care – Management

1. Antithrombotic Therapy

Every patient with TIA needs some form of antithrombotic therapy to prevent further cerebrovascular events, but the choice depends on whether the patient has atrial fibrillation or not.

TIA With No Atrial Fibrillation

Antiplatelets are the choice of antithrombotic therapy in the absence of AF (i.e., for thrombotic TIA)

There are 2 regimens recommended, depending on the patient’s bleeding risk.

Bleeding risk Antiplatelet regimen
Low bleeding risk (most cases)
  • Phase 1 (within 24 hours of TIA onset): offer a loading dose of DAPT (aspirin 300 mg + clopidogrel 300 mg)
  • Phase 2 (after 24 hours of TIA onset): maintenance dose DAPT for 21 days (aspirin 75 mg + clopidogrel 75 mg)
  • Phase 3 (after 21 days of DAPT): switch to clopidogrel 75 mg monotherapy lifelong

An alternative to clopidogrel is ticagrelor (loading dose: 180 mg, maintenance dose: 90 mg BD)

Logistics regarding phase 1:

When the patient is being reviewed by a specialist (within 24 hours), they would already have received a loading dose of aspirin 300 mg. The specialist would then just add the second antiplatelet agent to complete the DAPT (without repeating the initial aspirin dosing).

Note that in a non-specialist setting, only aspirin should be given. DAPT should only be given by a specialist.

High bleeding risk
  • Phase 1 (within 24 hours of TIA onset): loading dose of clopidogrel 300 mg
  • Phase 2 (after 24 hours of TIA onset): maintenance dose of clopidogrel 75 mg monotherapy lifelong

Note that DAPT is used in TIA but not in ischaemic stroke. This is due to the higher risk of haemorrhagic transformation in ischaemic stroke, which outweighs the potential benefits of DAPT.

Rationale in TIA: patients who experienced a TIA are at a substantial risk of further vascular events, and this risk is highest in the first few days. Large trials have demonstrated that early DAPT immediately after symptom onset (for 21 days) significantly reduces the rate of recurrent ischaemic strokes compared to using aspirin alone.

TIA With Atrial Fibrillation

Offer a non-contrast CT head to exclude intracerebral haemorrhage, then offer anticoagulation

  • 1st line for most patients: DOAC (e.g. apixaban, rivaroxaban)
  • 1st line in valvular AFwarfarin

Note the timing to start anticoagulation in TIA is different from that in ischaemic stroke:

  • In ischaemic stroke with AF (i.e. embolic stroke), anticoagulation is only started after 5-14 days, with only aspirin 300 mg being given during those 5-14 days
  • In TIA with AF (i.e. embolic TIA), anticoagulation can be started immediately, once intracerebral haemorrhage has been excluded

This difference in timing reflects the balance of benefits and bleeding risk in the presence of established infarction (stroke) vs TIA. Anticoagulants carry a much higher risk of intracerebral haemorrhage than antiplatelets.

  • In ischaemic stroke with AF, there is a significant risk of haemorrhagic transformation in the infarcted brain tissue if anticoagulation is started immediately. Therefore, anticoagulation is typically delayed for about 5-14 days, while aspirin 300 mg is given in this period to prevent early recurrent ischaemia.
  • In TIA with AF, there is no established infarcted tissue and thus essentially no risk of haemorrhagic transformation. Once intracerebral haemorrhage is excluded by imaging, anticoagulation can be started immediately to provide early secondary stroke prevention.

But ultimately, for both ischaemic stroke and TIA patients with AF, long-term anticoagulation (not antiplatelet therapy) is required for effective stroke prevention.

2. Other Secondary Prevention Strategies

All patients should receive the following:

  • Lifestyle advice (e.g. healthy diet, regular physical activity, smoking cessation, reduce alcohol intake)
  • High-intensity statin (usually atorvastatin 80 mg)
  • Optimise blood pressure control as per the Hypertension (Primary) article

3. Carotid Intervention

Do NOT routinely offer carotid intervention to all patients with TIA.

Indications for carotid intervention depend on the severity of stenosis (reported with the NASCET method):

Stenosis severity Management
Severe stenosis (50-99%) Perform carotid endarterectomy (on the problematic side only) within 7 days

If unfit for surgery → consider carotid angioplasty and stenting

Mild / moderate stenosis (<50%) NO intervention is necessary

DVLA Guidelines

Driving and TIA

After a stroke / TIA → always stop driving immediately.

Further action depends on the licence type:

Licence type Recommendation
Group 1 vehicle (car / motorcycle)
  • Stop driving for at least 1 month
  • There is no need to inform the DVLA routinely (unless there is residual neurological or cognitive deficit after 1 month, a seizure occurred, or brain surgery was performed)
Group 2 vehicle (bus / coach / lorry)
  • Must inform the DVLA
  • Stop driving for at least 1 year (12 months)

References

Related Articles

Stroke (Overview)

Ischaemic Stroke

Haemorrhagic Stroke

Subarachnoid haemorrhage (SAH)

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.